CVS/$CVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CVS
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health adds primary care services to the mix, which could have significant synergies with all existing business lines.
Ticker
$CVS
Sector
Primary listing
NYSE
Employees
259,500
Headquarters
Website
CVS Metrics
BasicAdvanced
$94B
20.61
$3.59
0.62
$2.66
3.59%
Price and volume
Market cap
$94B
Beta
0.62
52-week high
$75.55
52-week low
$43.56
Average daily volume
6.7M
Dividend rate
$2.66
Financial strength
Current ratio
0.803
Quick ratio
0.582
Long term debt to equity
92.35
Total debt to equity
106.67
Dividend payout ratio (TTM)
74.62%
Interest coverage (TTM)
3.05%
Profitability
EBITDA (TTM)
14,073
Gross margin (TTM)
13.30%
Net profit margin (TTM)
1.18%
Operating margin (TTM)
2.46%
Effective tax rate (TTM)
30.89%
Revenue per employee (TTM)
$1,480,000
Management effectiveness
Return on assets (TTM)
2.31%
Return on equity (TTM)
5.88%
Valuation
Price to earnings (TTM)
20.611
Price to revenue (TTM)
0.243
Price to book
1.21
Price to tangible book (TTM)
-2.34
Price to free cash flow (TTM)
19.537
Free cash flow yield (TTM)
5.12%
Free cash flow per share (TTM)
3.788
Dividend yield (TTM)
3.59%
Forward dividend yield
3.59%
Growth
Revenue change (TTM)
6.21%
Earnings per share change (TTM)
-36.25%
3-year revenue growth (CAGR)
7.78%
10-year revenue growth (CAGR)
10.19%
3-year earnings per share growth (CAGR)
-16.78%
10-year earnings per share growth (CAGR)
-1.41%
3-year dividend per share growth (CAGR)
8.20%
10-year dividend per share growth (CAGR)
7.84%
What the Analysts think about CVS
Analyst ratings (Buy, Hold, Sell) for CVS stock.
Bulls say / Bears say
CVS increased its 2025 earnings projection to $6.30–$6.40 per share after reporting Q2 adjusted EPS of $1.81, beating analyst expectations of $1.46. This marks the company's third straight quarterly earnings beat and suggests strong financial momentum (Reuters).
CVS’s Aetna insurance unit posted a Q2 2025 medical loss ratio of 89.9%, better than analysts’ estimate of 91.16%, reflecting stronger underwriting control and cost efficiency (Reuters).
Revenue in CVS’s health services segment climbed 10.2% and retail pharmacy sales jumped 12.5% year-over-year in Q2 2025, showing continued strong demand in its PBM, primary care, and pharmacy businesses (Reuters).
CVS plans to shut down 250 physical pharmacy locations in 2025 amid cost reduction strategies, pointing to persistent challenges in its retail division and suggesting possible short-term revenue pressure (Reuters).
Louisiana Attorney General Liz Murrill filed three lawsuits against CVS in June 2025, accusing its PBM unit of unfair, deceptive, and illegal practices. These cases highlight legal and regulatory risks that could lead to costly injunctions or required restitution (Reuters).
A Mercer survey in July 2025 showed 34% of large U.S. employers are considering moving away from traditional PBMs like CVS Caremark due to concerns about transparency and pricing, threatening Caremark’s market positioning (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
CVS Financial Performance
Revenues and expenses
CVS Earnings Performance
Company profitability
CVS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Oct23
CVS
DividendEx-dividend
Nov3
CVS
DividendPayment
$0.665Per share
FAQs
What’s the current market cap for CVS stock?
CVS (CVS) has a market cap of $94B as of September 18, 2025.
What is the P/E ratio for CVS stock?
The price to earnings (P/E) ratio for CVS (CVS) stock is 20.61 as of September 18, 2025.
Does CVS stock pay dividends?
Yes, the CVS (CVS) stock pays dividends to shareholders. As of September 18, 2025, the dividend rate is $2.66 and the yield is 3.59%. CVS has a payout ratio of 74.62% on a trailing twelve-month basis.
When is the next CVS dividend payment date?
The next CVS (CVS) dividend payment is scheduled for November 03, 2025.
What is the beta indicator for CVS?
CVS (CVS) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.